Diagnostic Value of Immunohistochemical IMP3 Expression in Core Needle Biopsies of Pancreatic Ductal Adenocarcinoma

Wachter, David; Schlabrakowski, Anne; Hoegel, Josef; Kristiansen, Glen; Hartmann, Arndt; Riener, Marc‐Oliver

doi:10.1097/pas.0b013e3182189223

Cited by 41 publications

(22 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IMP3 is considered an oncofetal protein that is expressed in fetal and carcinogenic tissue; however, the exact function of IMP3 remains unknown (7)(8)(9)(10)(11)(12). Expression of IMP3 has been studied in a wide variety of cancers, including renal cell carcinoma (13,14), adenocarcinoma of the uterine cervix (15), endometrial carcinoma (16), adenocarcinoma of the esophagus (17), malignant melanoma (18), Merkel cell carcinoma (19), urothelial carcinoma (20), neuroendocrine carcinoma of the lung (21), gastric adenocarcinoma (22), hepatocellular carcinoma (23), pancreatic (24)(25)(26)(27) and biliary tract (27) adenocarcinoma, and triple negative breast cancer (28), where this marker has frequently been associated with enhanced tumor aggressiveness and a worse outcome.…”

Section: Introductionmentioning

confidence: 99%

IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abstract. Expression of p16 has been established as a good surrogate marker for high-risk human papillomavirus (HPV) infection in oropharyngeal squamous cell carcinoma (OPSCC) patients, and it has been associated with an improved prognosis, irrespective of the actual HPV status. Conversely, the human insulin-like growth factor II mRNA binding protein 3 (IMP3) has been related to aggressiveness in several types of tumors. The aim of the present study was to investigate and compare p16 and IMP3 as markers of favorable and unfavorable behavior, respectively, in head and neck SCC (HNSCC), with particular reference to the HPV status. Both markers were analyzed by immunohistochemical analysis of 156 HNSCC samples originating from the oropharynx (n=81), oral cavity (n=44), larynx (n=15), hypopharynx (n=10) and nasopharynx (n=6). The HPV status was examined in a randomly selected representative subcohort (n=38) using polymerase chain reaction. Of the 156 HNSCC samples, 81 (51.9%) and 54 (34.6%) were positive for IMP3 and p16, respectively. IMP3 expression (P=0.022), p16 expression (P<0.001) and the combination of these markers (P<0.001) were significantly associated with tumor site. In particular, 69/81 (85%) OPSCC samples were positive for either one or both markers compared with 36/75 (48%) SCC samples from other sites. p16 expression was significantly associated with HPV infection (P= 0.017) and a trend towards a negative association between IMP3 expression and HPV infection was observed (P=0.053). The results of the present study suggested that IMP3 and p16 are more frequently expressed in OPSCC compared with other HNSCCs. The prognostic impact of IMP3 on OPSCC remains to be investigated in a larger series with an extended follow-up period. IntroductionSquamous cell carcinoma (SCC) is the leading cancer type affecting the head and neck region (HNSCC) representing >90% of malignant neoplasms of the oral cavity and oropharynx and 5 and 2% of all cancers in men and women, respectively (1). Tobacco smoking and alcohol consumption are the two major etiological factors of HNSCC and they work in a synergistic manner to initiate SCC (1). Approximately 75% of HNSCC cases in western countries are related to these two major risk factors, while the remainder is predominantly associated with viral infection, in particular infection with high-risk human papillomavirus (HPV) (1). HPV has been detected in a small fraction of oral cavity SCCs, and in 40-50% of oropharyngeal (mainly tonsillar) SCC (OPSCC) (1). While HPV-associated HNSCC may occur at any site, including the sinonasal tract, the majority of HPV-related SCCs originate in the lymphoid tissue bearing the oropharynx, mainly the palatine tonsil and the base of the tongue (1). Expression of p16 as a consequence of oncogenic HPV infection has been increasingly used as a surrogate marker for high-risk HPV infection, particularly in the female genital tract and the oropharynx (2,3). The sensitivity and specificity of p16 immunostaining for detecting high-risk HPV in OPSCC patie...

show abstract

Section: Introductionmentioning

confidence: 99%

IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, marked anisonucleosis/variation in nuclear size greater than four times in the same epithelial group and nuclear membrane irregularities (deep notch, deep groove, popcorn, or rasinoid) are nearly always absent in reactive conditions. Many tumor- 26 associated markers have been reported to be useful in the diagnosis of pancreatic adenocarcinoma [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. A recent study [42] investigates the utility of 26 different immunohistochemical markers cytokeratin panel (CAM 5.2, CK7, CK20, CK17, CK19), mucin panel (MUC1, MUC2, MUC4, MUC5AC, MUC6), tumor protein p53, tumor suppressor gene DPC4/SMA D4, CDX2 (a recently cloned homeobox gene that encodes an intestine-specific transcription factor, expressed in the nuclei of epithelial cells throughout the intestine, from duodenum to rectum), the Von Hippel-Lindau tumor suppressor protein (PVHL), the calcium binding protein S100 P, the Insulin-like growth factor II mRNA-binding protein 3 (IMP-3), mapsin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, Prostate stem cell antigen (PSCA), MOC31 antibody, also known as Epithelial Specific Antigen/Ep-CAM, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lewis (a) antigen (CA19-9) (Figures 2, 3) in the diagnosis of ductal adenocarcinoma of the pancreas.…”

Section: Reviewmentioning

confidence: 99%

EUS – Fine- Needle Aspiration Biopsy (FNAB) in the Diagnosis of Pancreatic Adenocarcinoma: A Review

Kalogeraki

Papadakis

Tamiolakis

et al. 2016

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Solid masses of the pancreas represent a variety of benign and malignant neoplasms of the exocrine and endocrine tissues of the pancreas. A tissue diagnosis is often required to direct therapy in the face of uncertain diagnosis or if the patient is not a surgical candidate either due to advanced disease or comorbidities. Endoscopic ultrasound (EUS) is a relatively new technology that employs endoscopy and high-frequency ultrasound (US). EUS involves imaging of the pancreatic head and the uncinate from the duodenum and imaging of the body and tail from the stomach. It has been shown to be a highly sensitive method for the detection of pancreatic masses. It is superior to extracorporeal US and computed tomographic (CT) scans, especially when the pancreatic tumor is smaller than 2-3 cm. Although EUS is highly sensitive in detecting pancreatic solid masses, its ability to differentiate between inflammatory masses and malignant disease is limited. Endoscopic retrograde cholangiopancreatography (ERCP) brushing, CT-guided biopsies, and transabdominal ultrasound (US) have been the standard nonsurgical methods for obtaining a tissue diagnosis of pancreatic lesions, but a substantial false-negative rate has been reported. Transabdominal US-guided fine-needle aspiration biopsy (US-FNAB) has been used for tissue diagnosis in patients with suspected pancreatic carcinoma. It has been shown to be highly specific, with no false-positive diagnoses. With the advent of curvilinear echoendoscopes, transgastric and transduodenal EUS-FNAB of the pancreas have become a reality EUS with FNAB has revolutionized the ability to diagnose and stage cancers of the gastrointestinal tract and assess the pancreas. Gastrointestinal cancers can be looked at with EUS and their depth of penetration into the intestinal wall can be determined. Any suspicious appearing lymph nodes can be biopsied using EUS/FNAB. The pancreas is another organ that is well visualized with EUS. Abnormalities such as tumors and cysts of the pancreas can be carefully evaluated using EUS and then biopsied with FNAB. There are many new applications of EUS using FNAB. Researchers are looking to deliver chemotherapeutics into small pancreatic cancers and cysts. Nerve blocks using EUS/FNAB to inject numbing medicines into the celiac ganglia, a major nerve cluster, are now routinely performed in patients with pain due to pancreatic cancer. The aim of this study is to perform a review of the literature regarding the usefulness of EUS/FNAB in the diagnosis of pancreatic adenocarcinoma.

show abstract

“…al investigated the expression level of an oncofetal protein, insulin-like growth factor II messenger ribonucleic acid-binding protein 3 (IMP3), which represent a marker for tumor aggressiveness in many different tumors (Wachter et al, 2011;Ozdemir et al, 2011).…”

Section: Identification Of New Potential Tumor Tissue Biomarkersmentioning

confidence: 99%

Novel Biomarkers in Pancreatic Cancer

Dima¹,

Tănase²,

Albulescu³

et al. 2012

Pancreatic Cancer - Clinical Management

View full text Add to dashboard Cite

Diagnostic Value of Immunohistochemical IMP3 Expression in Core Needle Biopsies of Pancreatic Ductal Adenocarcinoma

Cited by 41 publications

References 31 publications

IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis

IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis

EUS – Fine- Needle Aspiration Biopsy (FNAB) in the Diagnosis of Pancreatic Adenocarcinoma: A Review

Novel Biomarkers in Pancreatic Cancer

Contact Info

Product

Resources

About